{
    "xml": "<topic id=\"PHP2317\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/pipotiazine-palmitate\" basename=\"pipotiazine-palmitate\" title=\"PIPOTIAZINE PALMITATE\">\n<title>PIPOTIAZINE PALMITATE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_378\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/phenothiazines/pipotiazine\">Pipotiazine</xref>\n</p>\n<data name=\"vtmid\">349879008</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_716774613\" title=\"Antipsychotics (first-generation, depot injections)\">Antipsychotics (first-generation, depot injections)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" title=\"ANTIPSYCHOTIC DRUGS\" namespace=\"/drug-classes/antipsychotic-drugs\">ANTIPSYCHOTIC DRUGS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n<p outputclass=\"synonyms\">Pipothiazine Palmitate</p>\r\n</body>\n<topic id=\"PHP44151\" outputclass=\"indicationsAndDose\" rev=\"1.14\" parent=\"/drugs/pipotiazine-palmitate\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Maintenance in schizophrenia and other psychoses</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Test dose 25&#8239;mg, dose to be administered into the gluteal muscle, then 25&#8211;50&#8239;mg after 4&#8211;7&#8239;days, subsequently, adjusted according to response at intervals of 4 weeks; maintenance 50&#8211;100&#8239;mg every 4&#8239;weeks (max. per dose 200&#8239;mg).</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Initially 5&#8211;10&#8239;mg, dose to be administered into the gluteal muscle, then 25&#8211;50&#8239;mg after 4&#8211;7&#8239;days, subsequently, adjusted according to response at intervals of 4 weeks; maintenance 50&#8211;100&#8239;mg every 4&#8239;weeks (max. per dose 200&#8239;mg).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44178\" outputclass=\"contraindications\" rev=\"1.11\" parent=\"/drugs/pipotiazine-palmitate\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Children</ph>; <ph outputclass=\"contraindication\">CNS depression</ph>; <ph outputclass=\"contraindication\">comatose states</ph>; <ph outputclass=\"contraindication\">phaeochromocytoma</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44187\" outputclass=\"cautions\" rev=\"1.13\" parent=\"/drugs/pipotiazine-palmitate\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Hypothyroidism</ph>; <ph outputclass=\"caution\">thyrotoxicosis</ph>; <ph outputclass=\"caution\">when transferring from oral to depot therapy, the dose by mouth should be reduced gradually</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44124\" outputclass=\"sideEffects\" rev=\"1.9\" parent=\"/drugs/pipotiazine-palmitate\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Erythema</ph>; <ph outputclass=\"sideEffect\">nodules</ph>; <ph outputclass=\"sideEffect\">pain at injection site</ph>; <ph outputclass=\"sideEffect\">swelling</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44140\" outputclass=\"pregnancy\" parent=\"/drugs/pipotiazine-palmitate\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p>\n<p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44191\" outputclass=\"breastFeeding\" parent=\"/drugs/pipotiazine-palmitate\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid unless essential.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44159\" outputclass=\"hepaticImpairment\" parent=\"/drugs/pipotiazine-palmitate\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Can precipitate coma.</p>\n<p>Phenothiazines are hepatotoxic.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44130\" outputclass=\"renalImpairment\" parent=\"/drugs/pipotiazine-palmitate\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44107\" outputclass=\"monitoringRequirements\" parent=\"/drugs/pipotiazine-palmitate\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Treatment requires careful monitoring for optimum effect.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44211\" outputclass=\"directionsForAdministration\" rev=\"1.14\" parent=\"/drugs/pipotiazine-palmitate\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>In general not more than 2&#8211;3&#8239;mL of oily injection should be administered at any one site.</p>\n<p>Correct injection technique (including use of z-track technique) and rotation of injection sites are essential.</p>\n<p>When initiating therapy with sustained-release preparations of conventional antipsychotics, patients should first be given a small test-dose as undesirable side-effects are prolonged.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78155\" namespace=\"/treatment-summaries/psychoses-and-related-disorders\" title=\"Psychoses and related disorders\" count=\"1\" rel=\"backlink\">Psychoses and related disorders</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_378\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/phenothiazines/pipotiazine\" title=\"Pipotiazine\" count=\"1\" rel=\"link\">Pipotiazine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" namespace=\"/drug-classes/antipsychotic-drugs\" title=\"ANTIPSYCHOTIC DRUGS\" count=\"1\" rel=\"link\">ANTIPSYCHOTIC DRUGS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n</links>\n</topic>",
    "id": "PHP2317",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/pipotiazine-palmitate",
    "basename": "pipotiazine-palmitate",
    "title": "PIPOTIAZINE PALMITATE",
    "interactants": [
        {
            "id": "bnf_int_378",
            "label": "Pipotiazine"
        }
    ],
    "vtmid": "349879008",
    "drugClassification": [
        "Antipsychotics (first-generation, depot injections)"
    ],
    "inheritsFromClass": [
        "ANTIPSYCHOTIC DRUGS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "Pipothiazine Palmitate"
    ],
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Maintenance in schizophrenia and other psychoses",
                        "html": "Maintenance in schizophrenia and other psychoses"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection"
                    ],
                    "textContent": "By deep intramuscular injection",
                    "html": "By deep intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "Test dose 25 mg, dose to be administered into the gluteal muscle, then 25&#8211;50 mg after 4&#8211;7 days, subsequently, adjusted according to response at intervals of 4 weeks; maintenance 50&#8211;100 mg every 4 weeks (max. per dose 200 mg).",
                        "html": "<p>Test dose 25&#8239;mg, dose to be administered into the gluteal muscle, then 25&#8211;50&#8239;mg after 4&#8211;7&#8239;days, subsequently, adjusted according to response at intervals of 4 weeks; maintenance 50&#8211;100&#8239;mg every 4&#8239;weeks (max. per dose 200&#8239;mg).</p>"
                    },
                    {
                        "textContent": "Initially 5&#8211;10 mg, dose to be administered into the gluteal muscle, then 25&#8211;50 mg after 4&#8211;7 days, subsequently, adjusted according to response at intervals of 4 weeks; maintenance 50&#8211;100 mg every 4 weeks (max. per dose 200 mg).",
                        "html": "<p>Initially 5&#8211;10&#8239;mg, dose to be administered into the gluteal muscle, then 25&#8211;50&#8239;mg after 4&#8211;7&#8239;days, subsequently, adjusted according to response at intervals of 4 weeks; maintenance 50&#8211;100&#8239;mg every 4&#8239;weeks (max. per dose 200&#8239;mg).</p>",
                        "ageGroup": "elderly"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Children",
                "html": "Children"
            },
            {
                "type": "contraindications",
                "textContent": "CNS depression",
                "html": "CNS depression"
            },
            {
                "type": "contraindications",
                "textContent": "comatose states",
                "html": "comatose states"
            },
            {
                "type": "contraindications",
                "textContent": "phaeochromocytoma",
                "html": "phaeochromocytoma"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Hypothyroidism",
                "html": "Hypothyroidism"
            },
            {
                "type": "cautions",
                "textContent": "thyrotoxicosis",
                "html": "thyrotoxicosis"
            },
            {
                "type": "cautions",
                "textContent": "when transferring from oral to depot therapy, the dose by mouth should be reduced gradually",
                "html": "when transferring from oral to depot therapy, the dose by mouth should be reduced gradually"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Erythema",
                        "html": "Erythema",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nodules",
                        "html": "nodules",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pain at injection site",
                        "html": "pain at injection site",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "swelling",
                        "html": "swelling",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.",
                "html": "<p>If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.\n\nFollowing maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.",
                "html": "<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid unless essential.",
                "html": "<p>Avoid unless essential.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Can precipitate coma.\n\nPhenothiazines are hepatotoxic.",
                "html": "<p>Can precipitate coma.</p><p>Phenothiazines are hepatotoxic.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Start with small doses in severe renal impairment because of increased cerebral sensitivity.",
                "html": "<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Treatment requires careful monitoring for optimum effect.",
                "html": "<p>Treatment requires careful monitoring for optimum effect.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "In general not more than 2&#8211;3 mL of oily injection should be administered at any one site.\n\nCorrect injection technique (including use of z-track technique) and rotation of injection sites are essential.\n\nWhen initiating therapy with sustained-release preparations of conventional antipsychotics, patients should first be given a small test-dose as undesirable side-effects are prolonged.",
                "html": "<p>In general not more than 2&#8211;3&#8239;mL of oily injection should be administered at any one site.</p><p>Correct injection technique (including use of z-track technique) and rotation of injection sites are essential.</p><p>When initiating therapy with sustained-release preparations of conventional antipsychotics, patients should first be given a small test-dose as undesirable side-effects are prolonged.</p>"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78155",
                "label": "Psychoses and related disorders",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_378",
                "label": "Pipotiazine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34569",
                "label": "ANTIPSYCHOTIC DRUGS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ]
    }
}